Maxim Group analyst Jason McCarthy maintained a Buy rating on Pluristem (PSTI) today and set a price target of $3. The company’s shares opened today at $1.06, close to its 52-week low of $1.03.
McCarthy observed:
“Pluristem announced that it will present data from the first cohort of its Phase 1 study of PLX-R18 cells for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT) at the American Society of Hematology (ASH) 60th Annual Meeting & Exposition on December 1-4 in San Diego, CA.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -3.4% and a 34.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Pluristem has an analyst consensus of Moderate Buy, with a price target consensus of $3.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.65 and a one-year low of $1.03. Currently, Pluristem has an average volume of 218.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
